Skip to Main content Skip to Navigation
Journal articles

FOLFIRI(R) and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms.

Abstract : BACKGROUND: Over 50% of colorectal cancer (CRC) patients develop metastases. The aim of this study was to evaluate efficacy and tolerance of first-line FOLFIRI(R) + bevacizumab (B) treatment for metastatic CRC, and to assess genetic polymorphisms as potential markers. METHODS: Adult patients with histologically-proven, non-resectable metastatic CRC and ECOG <= 2 were included. 14-day cycles consisted of bevacizumab (5 mg/kg), irinotecan (180 mg/m2), bolus FU (400 mg/m2) and leucovorin (400 mg/m2), followed by 46-hour FU infusions (2400 mg/m2). Primary endpoint was response rate according to RECIST criteria. Secondary endpoints were overall (OS) and progression-free (PFS) survivals, response duration, and toxicity. Associations between clinical data, UGT1A1, thymidylate synthase, VEGFA polymorphisms and PFS, OS and toxicity were analyzed. RESULTS: Sixty-two patients were enrolled (median age 68y). 59/62 patients were eligible and evaluable for response at 6 months: 28 showed partial response (47.5%; 95%CI; 34.3-60.9), 20 stable disease (33.9%) and 11 progression (18.6%). Grade 3/4 toxicities were as follows: neutropenia 16.1%; diarrhea 11.3%; nausea-vomiting 1.6%. Median response duration was 9.5 months (range 2.7-20); median PFS 10.3 months (range 8.8-11.7); and median OS 25.7 months (range 20.2-29.7). 11/59 initially unresectable patients were resectable after treatment. VEGFA polymorphism (rs25648) was associated with better OS (HR: 3.61; 95%CI: 1.57-8.30). CONCLUSIONS: FOLFIRI(R) + bevacizumab is active with good response rate, long median OS, and a good safety profile. A VEGFA polymorphism might have a prognostic value in this malignancy.Trial registration: NCT00467142 (registration date: April 25, 2007).
Document type :
Journal articles
Complete list of metadata

Cited literature [38 references]  Display  Hide  Download
Contributor : Ed. BMC Connect in order to contact the contributor
Submitted on : Friday, May 2, 2014 - 9:19:55 PM
Last modification on : Thursday, June 11, 2020 - 3:19:39 AM
Long-term archiving on: : Saturday, August 2, 2014 - 12:31:58 PM




yves Bécouarn, Laurent Cany, Marina Pulido, Richard Beyssac, Patrick Texereau, et al.. FOLFIRI(R) and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms.. BMC Research Notes, BioMed Central, 2014, 7 (1), pp.260. ⟨10.1186/1756-0500-7-260⟩. ⟨inserm-00986609⟩



Record views


Files downloads